Thrombogenics DRC A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of a single intravitreal injection of THR-687 for the treatment of diabetic macular edema (DME)
Research Grant
Administered By
Ophthalmology
Awarded By
ThromboGenics Inc
Start Date
August 29, 2018
End Date
April 23, 2021
Administered By
Ophthalmology
Awarded By
ThromboGenics Inc
Start Date
August 29, 2018
End Date
April 23, 2021